Polymeric and Solid Lipid Nanoparticles in Cardiovascular Nano-Therapeutics

Abstract

Cardiovascular Diseases (CVD) rank as the primary global cause of death which results in more than 17 million deaths each year. Atherosclerosis and endothelial dysfunction and plaque instability start to develop in CVD patients because of inflammatory processes. The disease becomes worse because people lead unhealthy lives through their poor eating habits and inactive lifestyles and their use of tobacco and alcohol. Conventional treatments require replacement because of multiple issues that include low drug solubility and rapid systemic clearance and imprecise targeting abilities and off-target toxicity and multiple side effects that include dizziness and stroke and gastrointestinal bleeding and electrolyte imbalance. The drug delivery systems based on nanotechnology provide a new solution which enhances stability and bioavailability and targeted delivery for medical applications. The two most effective platforms for cardiovascular treatment among different nanocarriers are polymeric nanoparticles PNPs and solid lipid nanoparticles SLNs. The chapter investigates the new field of nanoparticles which includes Polymeric Nanoparticles and Solid Lipid Nanoparticles as a method for treating cardiovascular disease. The research studies how these nanoparticles differ from one another through their solubility and stability and bioavailability and capacity to target blood vessels. The research presents both the safety regulations and molecular pathways which these formulations control while discussing their essential elements which must be considered for safety and regulatory approval and control over production. The final section of the document examines current developments and upcoming developments which include hybrid nanocarriers and personalized nanotherapeutics.